nach oben

Current Gastroenterology Reports

Erschienen in:

01.10.2021 | Small Intestine (D Sachar, Section Editor)

The Intestinal Microbiome and Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Emerging Themes in the Management of Gastrointestinal Manifestations of Cystic Fibrosis

verfasst von: Daniel B. Karb, Linda C. Cummings

Erschienen in: Current Gastroenterology Reports | Ausgabe 10/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

While commonly associated with pulmonary manifestations, cystic fibrosis (CF) is a systemic disease with wide-ranging effects on the gastrointestinal (GI) tract. This article reviews major recent updates in gastroenterological CF care and research.

Recent Findings

The high burden of GI symptoms in CF has led to recent studies assessing GI-specific symptom questionnaires and scoring systems. Intestinal dysbiosis potentially contributes to gastrointestinal symptoms in patients with CF and an increased risk of gastrointestinal cancers in CF. An increased incidence of colorectal cancer (CRC) has led to CF-specific CRC screening and surveillance recommendations. Pharmacologic therapies targeting specific cystic fibrosis transmembrane conductance regulator (CFTR) mutations have shown promise in treating GI manifestations of CF.

Summary

New research has highlighted the importance of intestinal dysbiosis in CF. Future studies should assess whether CFTR modulators affect the gut microbiome and whether altering the gut microbiome will impact GI symptoms and GI cancer risk.

1.••

Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381:1809–19. https://doi.org/10.1056/NEJMoa1908639. This trial demonstrated efficacy of elexacaftor-tezacaftor-ivacaftor in patients with a F508del mutation and minimal function mutation in CFTR.

Brown SD, White R, Tobin P. Keep them breathing. J Am Acad Physician Assist. 2017;30:23–7. https://doi.org/10.1097/01.JAA.0000515540.36581.92.CrossRef

Festini F, Ballarin S, Codamo T, Doro R, Loganes C. Prevalence of pain in adults with cystic fibrosis. J Cyst Fibros. 2004;3:51–7. https://doi.org/10.1016/j.jcf.2003.12.001.CrossRefPubMed

Tabori H, Arnold C, Jaudszus A, Mentzel HJ, Renz DM, Reinsch S, et al. Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings. PLoS ONE. 2017;12(5): e0174463. https://doi.org/10.1371/journal.pone.0174463.CrossRefPubMedPubMedCentral

De Lisle RC, Borowitz D. The cystic fibrosis intestine. Cold Spring Harb Perspect Med. 2013;3(9): a009753. https://doi.org/10.1101/cshperspect.a009753.CrossRefPubMedPubMedCentral

Singh VK, Schwarzenberg SJ. Pancreatic insufficiency in Cystic Fibrosis. J Cyst Fibros. 2017;16:S70–8. https://doi.org/10.1016/j.jcf.2017.06.011.CrossRefPubMed

Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB. Cancer risk in cystic fibrosis: A 20-year nationwide study from the United States. J Natl Cancer Inst. 2013;105:122–9. https://doi.org/10.1093/jnci/djs481.CrossRefPubMed

Gelfond D, Borowitz D. Gastrointestinal complications of cystic fibrosis. Clin Gastroenterol Hepatol. 2013;11:333–42. https://doi.org/10.1016/j.cgh.2012.11.006.CrossRefPubMed

2017 Cystic Fibrosis Foundation Patient Registry Highlights. Cystic Fibrosis Foundation. 2018. https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2017-Cystic-Fibrosis-Foundation-Patient-Registry-Highlights.pdf. Accessed 8 May 2021.

10.••

Hayee B, Watson KL, Campbell S, Simpson A, Farrell E, Hutchings P, et al. A high prevalence of chronic gastrointestinal symptoms in adults with cystic fibrosis is detected using tools already validated in other GI disorders. United Eur Gastroenterol J. 2019;7:881–8. https://doi.org/10.1177/2050640619841545. Using validated GI tools, this study demonstrated that significant GI symptoms are common in adult patients with CF.

11.

Suzuki H. To establish a treatment for GI symptoms of cystic fibrosis, it is necessary to develop a symptom evaluation tool United. Eur Gastroenterol J. 2019;7:873–4. https://doi.org/10.1177/2050640619856188.CrossRef

12.••

Boon M, Claes I, Havermans T, Fornés-Ferrer V, Calvo-Lerma J, Asseiceira I, et al. Assessing gastro-intestinal related quality of life in cystic fibrosis: Validation of PedsQL GI in children and their parents. PLoS One. 2019;14(12):e0225004. https://doi.org/10.1371/journal.pone.0225004. This multicenter study validated a symptom measurement instrument gastrointestinal-related quality of life in children with CF.

13.

Varni JW, Bendo CB, Denham J, Shulman RJ, Self MM, Neigut DA, et al. PedsQL^TM Gastrointestinal Symptoms Scales and Gastrointestinal Worry Scales in pediatric patients with functional and organic gastrointestinal diseases in comparison to healthy controls. Qual Life Res. 2015;24:363–78. https://doi.org/10.1007/s11136-014-0781-x.CrossRefPubMed

14.

Varni JW, Franciosi JP, Shulman RJ, Saeed S, Nurko S, Neigut DA, et al. PedsQL gastrointestinal symptoms scales and gastrointestinal worry scales in pediatric patients with inflammatory bowel disease in comparison with healthy controls. Inflamm Bowel Dis. 2015;21:1115–24. https://doi.org/10.1097/MIB.0000000000000351.CrossRefPubMed

15.•

Smith S, Rowbotham N, Davies G, Gathercole K, Collins SJ, Elliott Z, et al. How can we relieve gastrointestinal symptoms in people with cystic fibrosis? An international qualitative survey. BMJ Open Respir Res. 2020;7:e000614. https://doi.org/10.1136/bmjresp-2020-000614. This survey study captured the burden of gastrointestinal symptoms in cystic fibrosis and their importance as a research priority.

16.•

Freeman AJ, Sathe M, Aliaj E, Borowitz D, Fogarty B, Goss CH, et al. Designing the GALAXY study: Partnering with the cystic fibrosis community to optimize assessment of gastrointestinal symptoms. J Cyst Fibros. 2021 Jan 13 [Epub ahead of print]. https://doi.org/10.1016/j.jcf.2020.12.021. This article describes a longitudinal study to assess the prevalence of gastointestinal symptoms in people with cystic fibrosis.

17.

Héry-Arnaud G, Boutin S, Cuthbertson L, Elborn SJ, Tunney MM. The lung and gut microbiome: what has to be taken into consideration for cystic fibrosis? J Cyst Fibros. 2019;18:13–21. https://doi.org/10.1016/j.jcf.2018.11.003.CrossRefPubMed

18.

Schnapp Z, Hartman C, Livnat G, Shteinberg M, Elenberg Y. Decreased fecal calprotectin levels in cystic fibrosis patients after antibiotic treatment for respiratory exacerbation. J Pediatr Gastroenterol Nutr. 2019;68:282–4. https://doi.org/10.1097/MPG.0000000000002197.CrossRefPubMed

19.

Antosca KM, Chernikova DA, Price CE, Ruoff KL, Li K, Guill MF, et al. Altered stool microbiota of infants with cystic fibrosis shows a reduction in genera associated with immune programming from birth. J Bacteriol. 2019;16:e00274-19. https://doi.org/10.1128/JB.00274-19.CrossRef

20.

Fouhy F, Ronan NJ, O’Sullivan O, McCarthy Y, Walsh AM, Murphy DM, et al. A pilot study demonstrating the altered gut microbiota functionality in stable adults with Cystic Fibrosis. Sci Rep. 2017;7:6685. https://doi.org/10.1038/s41598-017-06880-y.CrossRefPubMedPubMedCentral

21.••

Coffey MJ, Nielsen S, Wemheuer B, Kaakoush NO, Garg M, Needham B, et al. Gut Microbiota in Children With Cystic Fibrosis: A Taxonomic and Functional Dysbiosis. Sci Rep. 2019;9:18593. https://doi.org/10.1038/s41598-019-55028-7. This study demonstrated intestinal dysbiosis in children with cystic fibrosis compared with healthy controls and associations between the intestinal microbiome and both growth parameters and lung function.

22.

Vernocchi P, Del CF, Russo A, Majo F, Rossitto M, Valerio M, et al. Gut microbiota signatures in cystic fibrosis: Loss of host CFTR function drives the microbiota enterophenotype. PLoS One Public Lib Sci. 2018;13(12): e0208171. https://doi.org/10.1371/journal.pone.0208171.CrossRef

23.

Burke DG, Fouhy F, Harrison MJ, Rea MC, Cotter PD, O’Sullivan O, et al. The altered gut microbiota in adults with cystic fibrosis. BMC Microbiol. 2017;17:58. https://doi.org/10.1186/s12866-017-0968-8.CrossRefPubMedPubMedCentral

24.

Duytschaever G, Huys G, Bekaert M, Boulanger L, De Boeck K, Vandamme P. Cross-sectional and longitudinal comparisons of the predominant fecal microbiota compositions of a group of pediatric patients with cystic fibrosis and their healthy siblings. Appl Environ Microbiol. 2011;77:8015–24. https://doi.org/10.1128/AEM.05933-11.CrossRefPubMedPubMedCentral

25.

Nielsen S, Needham B, Leach ST, Day AS, Jaffe A, Thomas T, et al. Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis. Sci Rep. 2016;6:24857. https://doi.org/10.1038/srep24857.CrossRefPubMedPubMedCentral

26.

Hoen AG, Li J, Moulton LA, O’Toole GA, Housman ML, Koestler DC, et al. Associations between gut microbial colonization in early life and respiratory outcomes in cystic fibrosis. J Pediatr. 2015;167:138-147.e3. https://doi.org/10.1016/j.jpeds.2015.02.049.CrossRefPubMedPubMedCentral

27.

Madan JC, Koestle DC, Stanton BA, Davidson L, Moulton LA, Housman ML, et al. Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures. mBio. 2012;3(4):e00251-1251. https://doi.org/10.1128/mBio.00251-12.CrossRef

28.

Kristensen M, Prevaes SMPJ, Kalkman G, Tramper-Stranders GA, Hasrat R, de Winter, de Groot KM, et al. Development of the gut microbiota in early life: The impact of cystic fibrosis and antibiotic treatment. J Cyst Fibros. 2020;19:553–61. https://doi.org/10.1016/j.jcf.2020.04.007.CrossRefPubMed

29.

Burke DG, Harrison MJ, Fleming C, McCarthy M, Shortt C, Sulaiman I, et al. Clostridium difficile carriage in adult cystic fibrosis (CF); implications for patients with CF and the potential for transmission of nosocomial infection. J Cyst Fibros. 2017;16:291–8. https://doi.org/10.1016/j.jcf.2016.09.008.CrossRefPubMed

30.

Dorsey J, Gonska T. Bacterial overgrowth, dysbiosis, inflammation, and dysmotility in the Cystic Fibrosis intestine. J Cyst Fibros. 2017;16:S14-23. https://doi.org/10.1016/j.jcf.2017.07.014.CrossRefPubMed

31.

Hayden HS, Eng A, Pope CE, Brittnacher MJ, Vo AT, Weiss EJ, et al. Fecal dysbiosis in infants with cystic fibrosis is associated with early linear growth failure. Nat Med. 2020;26:215–21. https://doi.org/10.1038/s41591-019-0714-x.CrossRefPubMedPubMedCentral

32.

Adriaanse MPM, Van Der Sande LJTM, Van Den Neucker AM, Menheere PPCA, Dompeling E, Buurman WA, et al. Evidence for a cystic fibrosis enteropathy. PLoS ONE. 2015;10(10):e0138062. https://doi.org/10.1371/journal.pone.0138062.CrossRefPubMedPubMedCentral

33.

Parisi GF, Papale M, Rotolo N, Aloisio D, Tardino L, Scuderi MG, et al. Severe disease in cystic fibrosis and fecal calprotectin levels. Immunobiology. 2017;222:582–6. https://doi.org/10.1016/j.imbio.2016.11.005.CrossRefPubMed

34.

Ellemunter H, Engelhardt A, Schüller K, Steinkamp G. Fecal calprotectin in cystic fibrosis and its relation to disease parameters: a longitudinal analysis for 12 years. J Pediatr Gastroenterol Nutr. 2017;65(4):438–42. https://doi.org/10.1097/MPG.0000000000001544.CrossRefPubMed

35.

Enaud R, Hooks KB, Barre A, Barnetche T, Hubert C, Massot M, et al. Intestinal inflammation in children with cystic fibrosis is associated with Crohn’s-like microbiota disturbances. J Clin Med. 2019;8:645. https://doi.org/10.3390/jcm8050645.CrossRefPubMedCentral

36.

Flass T, Tong S, Frank DN, Wagner BD, Robertson CE, Kotter CV, et al. 2015 Intestinal Lesions are associated with altered intestinal microbiome and are more frequent in children and young adults with cystic fibrosis and cirrhosis. PLoS One. 2015;10:e0116967. https://doi.org/10.1371/journal.pone.0116967.CrossRefPubMedPubMedCentral

37.

Ananthan A, Balasubramanian H, Rao S, Patole S. Probiotic supplementation in children with cystic fibrosis—a systematic review. Eur J Pediatr. 2016;175(10):1255–66. https://doi.org/10.1007/s00431-016-2769-8.CrossRefPubMed

38.

Anderson JL, Miles C, Tierney AC. Effect of probiotics on respiratory, gastrointestinal and nutritional outcomes in patients with cystic fibrosis: a systematic review. J Cyst Fibros. 2017;16(2):186–97. https://doi.org/10.1016/j.jcf.2016.09.004.CrossRefPubMed

39.

Neri LDCL, Taminato M, Da Silva FLVRF. Systematic review of probiotics for cystic fibrosis patients: Moving forward. J Pediatr Gastroenterol Nutr. 2019;68(3):394–9. https://doi.org/10.1097/MPG.0000000000002185.CrossRefPubMed

40.•

Coffey MJ, Garg M, Homaira N, Jaffe A, Ooi CY. Probiotics for people with cystic fibrosis. Cochrane Database Syst Rev. 2020; Issue 1. Art. No.: CD012949. https://doi.org/10.1002/14651858.CD012949.pub2. This systematic review assessed the evidence for the use of probiotics in people with cystic fibrosis.

41.

Maisonneuve P, FitzSimmons SC, Neglia JP, Campbell PW, Lowenfels AB. Cancer risk in nontransplanted and transplanted cystic fibrosis patients: A 10-year study. J Natl Cancer Inst. 2003;95:381–7. https://doi.org/10.1093/jnci/95.5.381.CrossRefPubMed

42.

Fink AK, Yanik EL, Marshall BC, Wilschanski M, Lynch CF, Austin AA, et al. Cancer risk among lung transplant recipients with cystic fibrosis. J Cyst Fibros. 2017;16:91–7. https://doi.org/10.1016/j.jcf.2016.07.011.CrossRefPubMed

43.

Neglia JP, Fitzsimmons SC, Maisonneuve P, Schöni MH, Schöni-Affolter F, Corey M, et al. The risk of cancer among patients with cystic fibrosis. N Engl J Med. 1995;332:494–9. https://doi.org/10.1056/NEJM199502233320803.CrossRefPubMed

44.••

Hadjiliadis D, Khoruts A, Zauber AG, Hempstead SE, Maisonneuve P, Lowenfels AB, et al. Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations. Gastroenterology. 2018;154:736–745.e14. https://doi.org/10.1053/j.gastro.2017.12.012. This article provided consensus recommendations for colorectal cancer screening in patients with colorectal cancer.

45.

Than BLN, Linnekamp JF, Starr TK, Largaespada DA, Rod A, Zhang Y, et al. CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene. 2016;35:4191–9. https://doi.org/10.1038/onc.2015.483.CrossRef

46.

Pang T, Leach ST, Katz T, Jaffe A, Day AS, Ooi CY. Elevated fecal M2-pyruvate kinase in children with cystic fibrosis: A clue to the increased risk of intestinal malignancy in adulthood? J Gastroenterol Hepatol. 2015;30:866–71. https://doi.org/10.1111/jgh.12842.CrossRefPubMed

47.

Dayama G, Priya S, Niccum DE, Khoruts A, Blekhman R. Interactions between the gut microbiome and host gene regulation in cystic fibrosis. Genome Med. 2020;12:12. https://doi.org/10.1186/s13073-020-0710-2.CrossRefPubMedPubMedCentral

48.

Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A. 2006;103:12098–102. https://doi.org/10.1073/pnas.0603235103.CrossRefPubMedPubMedCentral

49.

Geng J, Song Q, Tang X, Liang X, Fan H, Peng H, et al. Co-occurrence of driver and passenger bacteria in human colorectal cancer. Gut Pathog. 2014;6:26. https://doi.org/10.1186/1757-4749-6-26.CrossRefPubMedPubMedCentral

50.

Collins FS. Realizing the DREAM OF MOLECULARLY TARGETED THERAPIES FOR CYSTIC FIBRosis. N Engl J Med. 2019;381:1863–5. https://doi.org/10.1056/NEJMe1911602.CrossRefPubMed

51.

Davies JC, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS, et al. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-years with cystic fibrosis and a CFTR gating mutation (KIWI): An open-label, single-arm study. Lancet Respir Med. 2016;4:107–15. https://doi.org/10.1016/S2213-2600(15)00545-7.CrossRefPubMedPubMedCentral

52.

Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, et al. A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation. N Engl J Med. 2011;365:1663–72. https://doi.org/10.1056/NEJMoa1105185.CrossRefPubMedPubMedCentral

53.

Davies JC, Wainwright CE, Canny GJ, Chilvers MA, Howenstine MS, Munck A, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013;187:1219–25. https://doi.org/10.1164/rccm.201301-0153OC.CrossRefPubMedPubMedCentral

54.

Rosenfeld M, Wainwright CE, Higgins M, Wang LT, McKee C, Campbell D, et al. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respir. 2018;6:545–53. https://doi.org/10.1016/S2213-2600(18)30202-9.CrossRef

55.

Rosenfeld M, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS, et al. An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2–5 years (KLIMB). J Cyst Fibros. 2019;18:838–43. https://doi.org/10.1016/j.jcf.2019.03.009.CrossRefPubMedPubMedCentral

56.

Borowitz D, Lubarsky B, Wilschanski M, Munck A, Gelfond D, Bodewes F, et al. Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor. Dig Dis Sci. 2016;61:198–207. https://doi.org/10.1007/s10620-015-3834-2.CrossRefPubMed

57.

2018 Patient Registry Annual Data Report. Cystic Fibrosis Foundation. 2019. https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2018-Patient-Registry-Annual-Data-Report.pdf. Accessed 8 May 2021.

58.

Dalemans W, Barbry P, Champigny G, Jallat S, Dott K, Dreyer D, et al. Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation. Nature. 1991;354:526–8. https://doi.org/10.1038/354526a0.CrossRefPubMed

59.

Lukacs GL, Chang XB, Bear C, Kartner N, Mohamed A, Riordan JR, et al. The ΔF508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. J Biol Chem. 1993;268:21592–8.CrossRef

60.

Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for phe508del CFTR. N Engl J Med. 2015;373:220–31. https://doi.org/10.1056/NEJMoa1409547.CrossRefPubMedPubMedCentral

61.

Konstan MW, McKone EF, Moss RB, Marigowda G, Tian S, Waltz D, et al. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med. 2017;5:107–18. https://doi.org/10.1016/S2213-2600(16)30427-1.CrossRefPubMed

62.

Hubert D, Chiron R, Camara B, Grenet D, Prévotat A, Bassinet L, et al. Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease. J Cyst Fibros. 2017;16:388–91. https://doi.org/10.1016/j.jcf.2017.03.003.CrossRefPubMed

63.

Labaste A, Ohlmann C, Mainguy C, Jubin V, Perceval M, Coutier L, et al. Real-life acute lung function changes after lumacaftor/ivacaftor first administration in pediatric patients with cystic fibrosis. J Cyst Fibros. 2017;16:709–12. https://doi.org/10.1016/j.jcf.2017.05.002.CrossRefPubMed

64.

Jennings MT, Dezube R, Paranjape S, West NE, Hong G, Braun A, et al. An observational study of outcomes and tolerances in patients with cystic fibrosis initiated on lumacaftor/ivacaftor. Ann Am Thorac Soc. 2017;14:1662–6. https://doi.org/10.1513/AnnalsATS.201701-058OC.CrossRefPubMed

65.

Schneider EK. Cytochrome P450 3A4 induction: lumacaftor versus ivacaftor potentially resulting in significantly reduced plasma concentration of ivacaftor. Drug Metab Lett. 2018;12:71–4. https://doi.org/10.2174/1872312812666180328105259.CrossRefPubMedPubMedCentral

66.

Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E, et al. Tezacaftor–ivacaftor in residual-function heterozygotes with cystic fibrosis. N Engl J Med. 2017;377:2024–35. https://doi.org/10.1056/NEJMoa1709847.CrossRefPubMedPubMedCentral

67.

Taylor-Cousar JL, Munck A, McKone EF, Van Der Ent CK, Moeller A, Simard C, et al. Tezacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N Engl J Med. 2017;377:2013–23. https://doi.org/10.1056/NEJMoa1709846.CrossRefPubMed

68.

Lommatzsch ST, Taylor-Cousar JL. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy. Ther Adv Respir Dis. 2019;13:1753466619844424. https://doi.org/10.1177/1753466619844424.CrossRefPubMedPubMedCentral

69.

SYMDEKO® (tezacaftor/ivacaftor) Package Insert. Vertex Pharmaceuticals Incorporated. 2019. https://pi.vrtx.com/files/uspi_tezacaftor_ivacaftor.pdf. Accessed 8 May 2021.

70.

Research Milestones. Cystic Fibrosis Foundation. Available from: https://www.cff.org/Research/About-Our-Research/Research-Milestones/ Accessed 27 Sep 2020.

71.

Ridley K, Condren M. Elexacaftor-tezacaftor-ivacaftor: The first triple-combination cystic fibrosis transmembrane conductance regulator modulating therapy. J Pediatr Pharmacol Ther. 2020;25:192–7. https://doi.org/10.5863/1551-6776-25.3.192.CrossRefPubMedPubMedCentral

72.••

Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 2019;394:1940–8. https://doi.org/10.1016/S0140-6736(19)32597-8. This trial demonstrated efficacy of elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis with a homozygous F508del mutation.

73.

Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, et al. A phase 3 open-label study of ELX/TEZ/IVA in children 6 through 11 years of age with cf and at least one F508del Allele. Am J Respir Crit Care Med. 2021. https://doi.org/10.1164/rccm.202102-0509oc.CrossRefPubMed

74.

Trikafta [package insert]. Vertex Pharmaceuticals Incorporated. 2020. https://pi.vrtx.com/files/uspi_elexacaftor_tezacaftor_ivacaftor.pdf. Accessed 8 May 2021.

75.

Cystic Fibrosis Agents. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2018. https://www.ncbi.nlm.nih.gov/books/NBK547889/ Accessed 27 Sep 2020.

76.

Bessonova L, Volkova N, Higgins M, Bengtsson L, Tian S, Simard C, et al. Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Thorax. 2018;73:731–40. https://doi.org/10.1136/thoraxjnl-2017-210394.CrossRefPubMed

77.

Sergeev V, Chou FY, Lam GY, Hamilton CM, Wilcox PG, Quon BS. The extrapulmonary effects of cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis. Ann Am Thorac Soc. 2020;17:147–54. https://doi.org/10.1513/AnnalsATS.201909-671CME.CrossRefPubMedPubMedCentral

78.

Kutney K, Donnola SB, Flask CA, Gubitosi-Klug R, O’Riordan M, Mcbennett K, et al. Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients. World J Hepatol. 2019;11:761–72. https://doi.org/10.4254/wjh.v11.i12.761.CrossRefPubMedPubMedCentral

79.

van de Peppel IP, Doktorova M, Berkers G, de Jonge HR, Houwen RHJ, Verkade HJ, et al. IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation. J Cyst Fibros. 2019;18:286–93. https://doi.org/10.1016/j.jcf.2018.09.001.CrossRefPubMed

80.

Carrion A, Borowitz DS, Freedman SD, Siracusa CM, Goralski JL, Hadjiliadis D, et al. Reduction of recurrence risk of pancreatitis in cystic fibrosis with ivacaftor: case series. J Pediatr Gastroenterol Nutr. 2018;66:451–4. https://doi.org/10.1097/MPG.0000000000001788.CrossRefPubMed

81.

Bellin MD, Laguna T, Leschyshyn J, Regelmann W, Dunitz J, Billings J, et al. Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study. Pediatr Diabetes. 2013;14:417–21. https://doi.org/10.1111/pedi.12026.CrossRefPubMedPubMedCentral

82.

Christian F, Thierman A, Shirley E, Allen K, Cross C, Jones K. Sustained glycemic control with ivacaftor in cystic fibrosis–related diabetes. J Investig Med High Impact Case Rep. 2019. https://doi.org/10.1177/2324709619842898.CrossRefPubMedPubMedCentral

83.

Hayes D, McCoy KS, Sheikh SI. Resolution of cystic fibrosis-related diabetes with ivacaftor therapy. Am J Respir Crit Care Med. 2014;190:590–1. https://doi.org/10.1164/rccm.201405-0882LE.CrossRefPubMed

84.

Tsabari R, Elyashar HI, Cymberknowh MC, Breuer O, Armoni S, Livnat G, et al. CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation. J Cyst Fibros. 2016;15:e25–7. https://doi.org/10.1016/j.jcf.2015.10.012.CrossRefPubMed

85.

Mutyam V, Libby EF, Peng N, Hadjiliadis D, Bonk M, Solomon GM, et al. Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation. J Cyst Fibros. 2017;16:24–9. https://doi.org/10.1016/j.jcf.2016.09.005.CrossRefPubMed

86.

McNamara JJ, McColley SA, Marigowda G, Liu F, Tian S, Owen CA, et al. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. Lancet Respir Med. 2019;7:325–35. https://doi.org/10.1016/S2213-2600(18)30460-0.CrossRefPubMed

87.

Ratjen F, Hug C, Marigowda G, Tian S, Huang X, Stanojevic S, et al. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2017;5:557–67. https://doi.org/10.1016/S2213-2600(17)30215-1.CrossRefPubMed

88.••

Ooi CY, Syed SA, Rossi L, Garg M, Needham B, Avolio J, et al. Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation. Sci Rep. 2018;8:17834. https://doi.org/10.1038/s41598-018-36364-6. This study demonstrated associations between ivacaftor therapy and changes in the gut microbiome as well as decreased intestinal inflammation.

89.

Zeybel GL, Pearson JP, Krishnan A, Bourke SJ, Doe S, Anderson A, et al. Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation. J Cyst Fibros. 2017;16:124–31. https://doi.org/10.1016/j.jcf.2016.07.004.CrossRefPubMedPubMedCentral

90.

Hjelm M, Shaikhkhalil AK. Celiac Disease in Patients With Cystic Fibrosis on Ivacaftor: A Case Series. J Pediatr Gastroenterol Nutr. 2020;71:257–60. https://doi.org/10.1097/MPG.0000000000002736CrossRefPubMed

91.

Gelfond D, Heltshe S, Ma C, Rowe SM, Frederick C, Uluer A, et al. Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation. Clin Transl Gastroenterol. 2017;8(3): e81. https://doi.org/10.1038/ctg.2017.10.CrossRefPubMedPubMedCentral

Titel: The Intestinal Microbiome and Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Emerging Themes in the Management of Gastrointestinal Manifestations of Cystic Fibrosis
verfasst von: Daniel B. Karb
Linda C. Cummings
Publikationsdatum: 01.10.2021
Verlag: Springer US
Erschienen in: Current Gastroenterology Reports / Ausgabe 10/2021
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI: https://doi.org/10.1007/s11894-021-00817-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

The Intestinal Microbiome and Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Emerging Themes in the Management of Gastrointestinal Manifestations of Cystic Fibrosis

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Update Innere Medizin

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Update Innere Medizin